{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:22:46Z","timestamp":1777580566059,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The selective alpha-2 agonist brimonidine was used as a pharmacological probe to activate \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      receptor-mediated neuroprotective signaling pathways and quantitate the enhancement of retinal ganglion cell survival and function in animals with ischemic retinal and optic nerve injury.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two animal models were used to achieve different methods of neuronal insult. The first model involved mechanical injury of the rat optic nerve after treatment with a single intraperitoneal (IP) dose of brimonidine or a control vehicle. The second model involving acute retinal ischemic\/reperfusion injury was used in a variety of experiments in which rats were treated with either intraperitoneal brimonidine or single dose topical brimonidine at various strengths. In all cases retinal ischemia was induced and maintained followed by reperfusion. In some cases, TUNEL staining was performed on histologic sections of the retinas of rats that had been sacrificed after 24 hours. To examine the activation of neuronal survival pathways at the molecular level, rats were injected with IP brimonidine followed by the isolation of mRNAs from whole retinas 24 hours after ischemic injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Intraperitoneal brimonidine enhanced rat RGC survival and function in the partial crush injury model, and neuroprotection was dose-dependent. Topical application of brimonidine 1 hour before injury was effective in decreasing ischemic retinal injury. Ischemic retinas treated with brimonidine resulted with a large decrease in TUNEL staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment with the \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      adrenoreceptor agonist brimonidine was found to confer neuroprotection to retinal ganglion cells in two distinct models of neuronal injury resulting from acute retinal ischemia\/reperfusion and calibrated optic nerve compression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/112067219900901s09","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T07:27:25Z","timestamp":1530516445000},"source":"Crossref","is-referenced-by-count":56,"title":["From the Lab to the Clinic: Activation of an Alpha-2 agonist Pathway is Neuroprotective in Models of Retinal and Optic Nerve Injury"],"prefix":"10.1177","volume":"9","author":[{"given":"L.A.","family":"Wheeler","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Allergan Inc., Irvine, CA - U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Allergan Inc., Irvine, CA - U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Woldemussie","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Allergan Inc., Irvine, CA - U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"774","article-title":"Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis","volume":"36","author":"Quigley H.A.","year":"1995","unstructured":"QuigleyH.A., NickellsR.W., KerriganL.A. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36: 774\u201386.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(97)00013-0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160201010"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199610000-00010"},{"key":"e_1_2_1_6_2","first-page":"1618","article-title":"Chronic low-dose glutamate is toxic to retinal ganglion cells","volume":"37","author":"Vorwerk C.K.","year":"1996","unstructured":"VorwerkC.K., LiptonS.A., ZurakowskiD. Chronic low-dose glutamate is toxic to retinal ganglion cells. Invest Ophthalmol Vis Sci 1996; 37: 1618\u201324.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.3233\/RNN-1990-2104"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.7.906"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4835(95)80056-5"},{"key":"e_1_2_1_10_2","first-page":"65","article-title":"Alpha-2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration","volume":"40","author":"Yoles E.","year":"1999","unstructured":"YolesE., WheelerL.A., SchwartzM. Alpha-2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40: 65\u201373.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(97)00356-X"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(87)90708-7"},{"key":"e_1_2_1_13_2","first-page":"489","article-title":"Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells","volume":"37","author":"Peinado-Ramon P.","year":"1996","unstructured":"Peinado-RamonP., SalvadorM., Villegas-PerezMP, Vidal-SanzM. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1996; 37: 489\u2013500.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_14_2","first-page":"3163","article-title":"Effects of basic fibroblast growth factor in retinal ischemia","volume":"35","author":"Zhang C.","year":"1994","unstructured":"ZhangC., TakahasiK., LamT.T., TsoM.O. Effects of basic fibroblast growth factor in retinal ischemia. Invest Ophthalmol Vis Sci 1994; 35: 3163\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-19-05986.1996"},{"key":"e_1_2_1_16_2","first-page":"1721","article-title":"Alpha-2-adrenergic agonists selectively activate extracellular signal-regulated kinases in M\u00fcller cells in vivo","volume":"39","author":"Peng M.","year":"1998","unstructured":"PengM., YiwenL., ZhijunL., LiuC., LattesA., WenR. Alpha-2-adrenergic agonists selectively activate extracellular signal-regulated kinases in M\u00fcller cells in vivo. Invest Ophthalmol Vis Sci 1998; 39: 1721\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_17_2","first-page":"72","article-title":"Functional protection of rat retina ischemic injury by brimonidine","volume":"23","author":"Hasson D.","year":"1997","unstructured":"HassonD., LaiR.K., ChunT., WheelerL.A. Functional protection of rat retina ischemic injury by brimonidine. Soc Neurosci 1997; 23: 72\u20134.","journal-title":"Soc Neurosci"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.395"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067219900901S09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067219900901S09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:43:06Z","timestamp":1777405386000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/112067219900901S09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":17,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1177\/112067219900901S09"],"URL":"https:\/\/doi.org\/10.1177\/112067219900901s09","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}